Your session is about to expire
← Back to Search
Adaptive Neoadjuvant Chemotherapy for Pancreatic Cancer (PANC Trial)
PANC Trial Summary
This trial is testing a new treatment for people with pancreas cancer that has not spread.
PANC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPANC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 3 trial • 688 Patients • NCT00424255PANC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer diagnosis was confirmed through a biopsy.My blood and organ tests meet the required levels for treatment.I haven't had a CA19-9 test done before starting chemotherapy when my bilirubin was low.I am either not able to have children, using birth control, or have a negative pregnancy test.I have had chemotherapy or radiation in the last 3 years.I can do most of my daily activities without help.I am 18 years old or older.I have HIV, HBV, or HCV.I have had another type of cancer in the last 3 years.My pancreatic cancer is at a stage where surgery might be possible.I have been treated with FOLFIRINOX or mFOLFIRINOX for over two months.You have uncontrolled health problems like serious infections, heart conditions, or psychiatric illness, or you are unable to follow the study rules or give your consent.My CA19-9 levels are high, but my bilirubin is low.
- Group 1: Restaging: Patients with Stable Disease
- Group 2: Restaging: Local Disease Progression
- Group 3: Restaging: Response to Treatment
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned chemoradiation therapy?
"Chemoradiation's safety is rated 2, as the Phase 2 trial has only provided data demonstrating its security but not its effectiveness."
Are there any vacancies for prospective participants in this experiment?
"Affirmative, clinicaltrials.gov data indicates that enrollment is ongoing for this medical trial. Initially posted on June 21st 2018 and updated most recently in July 29th 2022, the study seeks 125 patients from a single centre of research."
Are there any analogous experiments involving the combination of chemotherapy and radiation therapy?
"Presently, there are 1013 Chemoradiation trials ongoing worldwide. Of those, 312 are in Phase 3. The greatest concentration of these studies is located in Guangzhou, Guangdong; however, the data indicates that 48793 different institutions have launched or will launch research into Chemoradiation therapy."
How many participants are enrolled in this research?
"Absolutely. Data available from clinicaltrials.gov proves that this medical trial, which was first published on June 21st 2018, is actively recruiting participants. A total of 125 volunteers must be sourced from a single site for the study to continue as planned."
To what ailments is Chemoradiation routinely recommended?
"Chemoradiation is a standard therapy for cases of non-small cell lung carcinoma, rectal carcinoma and colorectal carcinoma."
Share this study with friends
Copy Link
Messenger